Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer

Completed · Phase 1

Conditions studied: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific

In brief

Phase I trial to study the effectiveness of rebeccamycin analog and cisplatin with or without filgrastim in treating patients who have advanced cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy.

Key facts

Study ID

NCT00004189

Run by

National Cancer Institute (NCI)

People needed

40

Starts

1999-10-01

Last updated by the study team

2013-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States
• Cancer Therapy and Research Center — San Antonio, Texas, United States
• St. Luke's Lutheran Hospital — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.